Market Cap | 93.63M | P/E | - | EPS this Y | 27.90% | Ern Qtrly Grth | - |
Income | -30.7M | Forward P/E | -1.70 | EPS next Y | -87.10% | 50D Avg Chg | -10.00% |
Sales | 56.54M | PEG | -0.04 | EPS past 5Y | - | 200D Avg Chg | -4.00% |
Dividend | N/A | Price/Book | 3.49 | EPS next 5Y | 61.20% | 52W High Chg | -50.00% |
Recommedations | 1.60 | Quick Ratio | 1.45 | Shares Outstanding | 90.62M | 52W Low Chg | 126.00% |
Insider Own | 7.53% | ROA | -30.38% | Shares Float | 76.81M | Beta | 1.01 |
Inst Own | 30.63% | ROE | -358.92% | Shares Shorted/Prior | 195.38K/221.36K | Price | 1.04 |
Gross Margin | -30.22% | Profit Margin | -54.29% | Avg. Volume | 876,140 | Target Price | 5.60 |
Oper. Margin | -67.27% | Earnings Date | Apr 18 | Volume | 710,387 | Change | 0.00% |
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
HC Wainwright & Co. | Buy | Apr 8, 24 |
HC Wainwright & Co. | Buy | Dec 7, 23 |
HC Wainwright & Co. | Buy | Nov 6, 23 |
Needham | Buy | Sep 22, 23 |
HC Wainwright & Co. | Buy | Sep 22, 23 |
Needham | Buy | Sep 8, 23 |
HC Wainwright & Co. | Buy | Sep 7, 23 |
HC Wainwright & Co. | Buy | Aug 7, 23 |
Needham | Buy | Aug 4, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Tari Leslie | CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER | Aug 14 | Buy | 0.97 | 10,000 | 9,700 | 294,179 | 08/14/23 |
Stein Jeffrey | President & CEO President & CEO | Aug 08 | Buy | 0.9577 | 50,000 | 47,885 | 331,602 | 08/08/23 |
Stein Jeffrey | President & CEO President & CEO | Mar 27 | Buy | 1.0371 | 50,000 | 51,855 | 281,602 | 03/27/23 |
Ward Shane | COO & CLO COO & CLO | Mar 13 | Sell | 1.53 | 4,329 | 6,623 | 84,576 | 03/13/23 |
Tari Leslie | CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER | Mar 13 | Sell | 1.53 | 7,562 | 11,570 | 190,179 | 03/13/23 |
Shah Preetam | CFO & CBO CFO & CBO | Mar 13 | Sell | 1.53 | 6,648 | 10,171 | 148,141 | 03/13/23 |
Sandison Taylor | Chief Medical Office.. Chief Medical Officer | Mar 13 | Sell | 1.53 | 7,203 | 11,021 | 288,550 | 03/13/23 |
Sandison Taylor | Chief Medical Office.. Chief Medical Officer | Sep 12 | Sell | 0.6849 | 18,478 | 12,656 | 291,753 | 09/13/22 |
Tari Leslie | CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER | Sep 12 | Sell | 0.6849 | 18,159 | 12,437 | 193,741 | 09/13/22 |
Daruwala Paul | Chief Operating Offi.. Chief Operating Officer | Sep 12 | Sell | 0.6849 | 16,199 | 11,095 | 221,099 | 09/13/22 |
Johnson Brady | Vice President, Fina.. Vice President, Finance | Mar 21 | Sell | 0.81 | 654 | 530 | 49,366 | 03/23/22 |
Johnson Brady | Vice President, Fina.. Vice President, Finance | Mar 11 | Sell | 0.71 | 945 | 671 | 50,020 | 03/11/22 |
Daruwala Paul | Chief Operating Offi.. Chief Operating Officer | Dec 29 | Option | 0 | 9,900 | 192,431 | 01/07/22 | |
Daruwala Paul | Chief Operating Offi.. Chief Operating Officer | Dec 29 | Sell | 1.25 | 5,133 | 6,416 | 187,298 | 01/07/22 |
Stein Jeffrey | President & CEO President & CEO | Dec 29 | Option | 0.00 | 20,000 | 489,878 | 01/07/22 | |
Johnson Brady | Vice President, Fina.. Vice President, Finance | Dec 29 | Option | 0 | 262 | 51,381 | 01/07/22 | |
Johnson Brady | Vice President, Fina.. Vice President, Finance | Dec 29 | Sell | 1.25 | 416 | 520 | 50,965 | 01/07/22 |
Sandison Taylor | Chief Medical Office.. Chief Medical Officer | Dec 29 | Option | 0.00 | 15,600 | 256,231 | 01/07/22 | |
Tari Leslie | Chief Scientific Off.. Chief Scientific Officer | Dec 29 | Option | 0 | 2,101 | 156,652 | 01/07/22 | |
Tari Leslie | Chief Scientific Off.. Chief Scientific Officer | Dec 29 | Sell | 1.25 | 1,252 | 1,565 | 155,400 | 01/07/22 |
Daruwala Paul | Chief Operating Offi.. Chief Operating Officer | Apr 05 | Sell | 2.36 | 3,461 | 8,168 | 50,531 | 04/05/21 |